Cargando…
Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies
OBJECTIVES: Pharmacoepidemiological studies are an important hypothesis-testing tool in the evaluation of postmarketing drug safety. Despite the potential to produce robust value-added data, interpretation of findings can be hindered due to well-recognised methodological limitations of these studies...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467649/ https://www.ncbi.nlm.nih.gov/pubmed/23015600 http://dx.doi.org/10.1136/bmjopen-2012-001362 |
_version_ | 1782245851580596224 |
---|---|
author | Neyarapally, George A Hammad, Tarek A Pinheiro, Simone P Iyasu, Solomon |
author_facet | Neyarapally, George A Hammad, Tarek A Pinheiro, Simone P Iyasu, Solomon |
author_sort | Neyarapally, George A |
collection | PubMed |
description | OBJECTIVES: Pharmacoepidemiological studies are an important hypothesis-testing tool in the evaluation of postmarketing drug safety. Despite the potential to produce robust value-added data, interpretation of findings can be hindered due to well-recognised methodological limitations of these studies. Therefore, assessment of their quality is essential to evaluating their credibility. The objective of this review was to evaluate the suitability and relevance of available tools for the assessment of pharmacoepidemiological safety studies. DESIGN: We created an a priori assessment framework consisting of reporting elements (REs) and quality assessment attributes (QAAs). A comprehensive literature search identified distinct assessment tools and the prespecified elements and attributes were evaluated. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure was the percentage representation of each domain, RE and QAA for the quality assessment tools. RESULTS: A total of 61 tools were reviewed. Most tools were not designed to evaluate pharmacoepidemiological safety studies. More than 50% of the reviewed tools considered REs under the research aims, analytical approach, outcome definition and ascertainment, study population and exposure definition and ascertainment domains. REs under the discussion and interpretation, results and study team domains were considered in less than 40% of the tools. Except for the data source domain, quality attributes were considered in less than 50% of the tools. CONCLUSIONS: Many tools failed to include critical assessment elements relevant to observational pharmacoepidemiological safety studies and did not distinguish between REs and QAAs. Further, there is a lack of considerations on the relative weights of different domains and elements. The development of a quality assessment tool would facilitate consistent, objective and evidence-based assessments of pharmacoepidemiological safety studies. |
format | Online Article Text |
id | pubmed-3467649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34676492012-10-19 Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies Neyarapally, George A Hammad, Tarek A Pinheiro, Simone P Iyasu, Solomon BMJ Open Epidemiology OBJECTIVES: Pharmacoepidemiological studies are an important hypothesis-testing tool in the evaluation of postmarketing drug safety. Despite the potential to produce robust value-added data, interpretation of findings can be hindered due to well-recognised methodological limitations of these studies. Therefore, assessment of their quality is essential to evaluating their credibility. The objective of this review was to evaluate the suitability and relevance of available tools for the assessment of pharmacoepidemiological safety studies. DESIGN: We created an a priori assessment framework consisting of reporting elements (REs) and quality assessment attributes (QAAs). A comprehensive literature search identified distinct assessment tools and the prespecified elements and attributes were evaluated. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure was the percentage representation of each domain, RE and QAA for the quality assessment tools. RESULTS: A total of 61 tools were reviewed. Most tools were not designed to evaluate pharmacoepidemiological safety studies. More than 50% of the reviewed tools considered REs under the research aims, analytical approach, outcome definition and ascertainment, study population and exposure definition and ascertainment domains. REs under the discussion and interpretation, results and study team domains were considered in less than 40% of the tools. Except for the data source domain, quality attributes were considered in less than 50% of the tools. CONCLUSIONS: Many tools failed to include critical assessment elements relevant to observational pharmacoepidemiological safety studies and did not distinguish between REs and QAAs. Further, there is a lack of considerations on the relative weights of different domains and elements. The development of a quality assessment tool would facilitate consistent, objective and evidence-based assessments of pharmacoepidemiological safety studies. BMJ Group 2012-09-26 /pmc/articles/PMC3467649/ /pubmed/23015600 http://dx.doi.org/10.1136/bmjopen-2012-001362 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Epidemiology Neyarapally, George A Hammad, Tarek A Pinheiro, Simone P Iyasu, Solomon Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title | Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title_full | Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title_fullStr | Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title_full_unstemmed | Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title_short | Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
title_sort | review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467649/ https://www.ncbi.nlm.nih.gov/pubmed/23015600 http://dx.doi.org/10.1136/bmjopen-2012-001362 |
work_keys_str_mv | AT neyarapallygeorgea reviewofqualityassessmenttoolsfortheevaluationofpharmacoepidemiologicalsafetystudies AT hammadtareka reviewofqualityassessmenttoolsfortheevaluationofpharmacoepidemiologicalsafetystudies AT pinheirosimonep reviewofqualityassessmenttoolsfortheevaluationofpharmacoepidemiologicalsafetystudies AT iyasusolomon reviewofqualityassessmenttoolsfortheevaluationofpharmacoepidemiologicalsafetystudies |